The fluorometric microculture cytotoxicity assay

Nature Protocols

Volumn 3, Issue 8, 2008, Pages 1364-1369

  Lindhagen, Elin ^a   Nygren, Peter ^a   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CHLORAMBUCIL; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ESTERASE; ETOPOSIDE; FLUORESCEIN DIACETATE; FLUOROURACIL; MELPHALAN; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG SCREENING; FLUOROMETRY; FREEZING; HUMAN; HUMAN CELL; IN VITRO STUDY; LABORATORY AUTOMATION; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; ROBOTICS;

ANTINEOPLASTIC AGENTS; CELL COUNT; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CYTOTOXINS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; FLUORESCEINS; FLUOROMETRY; FLUOROURACIL; HALF-LIFE; HUMANS; TOXICITY TESTS;

EID: 50349098488     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2008.114     Document Type: Article

References (18)

1. Blumenthal, R.D. An overview of chemosensitivity testing. Methods Mol. Med. 110, 3-18 (2005).
2. Larsson, R., Kristensen, J., Sandberg, C. & Nygren, P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer 50, 177-185 (1992).
3. Larsson, R., Nygren, P., Ekberg, M. & Slater, L. Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia 4, 567-571 (1990).
4. Rubinstein, L.V. et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82, 1113-1118 (1990).
5. Dhar, S. et al. Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J. Cancer 74, 888-896 (1996).
6. Fridborg, H., Jonsson, E., Nygren, P. & Larsson, R. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur. J. Cancer 35, 424-432 (1999).
7. Hjarnaa, P.J. et al. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res. 59, 5751-5757 (1999).
8. Lindhagen, E. et al. Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro. Invest. New Drugs 25, 297-303 (2007).
9. Wickstrom, M. et al. The novel alkylating prodrug J1: Diagnosis directed activity profile ex vivo and combination analyses in vitro. Invest. New Drugs 26, 195-204 (2007).
10. Fryknas, M. et al. Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model. J. Biomol. Screen. 11, 457-468 (2006).
11. Hassan, S.B., Jonsson, E., Larsson, R. & Karlsson, M.O. Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. J. Pharmacol. Exp. Ther. 299 1140-1147 (2001).
12. Lindhagen, E. et al. R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemother. Pharmacol. 60, 545-553 (2007).
13. Bosanquet, AG., Nygren, P. & Weisenthal, LM. Individualized tumor response testing in leukemia and lymphoma. In: Innovative Leukemia and Lymphoma Therapy (eds. Kaspers, G.J.L., Coiffier, B., Heinrich, M.C. & Estey, E.H.) (Informa Healthcare, New York, 2008).
14. Hassan, S.B. et al. Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity. Toxicol. In Vitro 21 1174-1181 (2007).
15. Csoka, K. et al. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol. Oncol. 54, 163-170 (1994).
16. Larsson, R. & Nygren, P. Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off Limits and a Bayesian model. Anticancer Res. 13, 1825-1829 (1993).
17. Nygren, P. et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 6, 1121-1128 (1992).
18. Fridborg, H. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) in the preclinical evaluation of anticancer drugs. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine no. 650, (Acta Universitatis Upsaliensis, Uppsala, Sweden, 1996).